Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 2-Year Results from the Phase 3 SELECT-PsA 1 Study

Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 2-Year Results from the Phase 3 SELECT-PsA 1 Study

Abstract Introduction Efficacy and safety of the Janus kinase (JAK) inhibitor upadacitinib (UPA) was evaluated in patients with psoriatic arthritis (PsA) through week 104 of the ongoing long-term extension of the phase 3 trial SELECT-PsA 1. Methods Exploratory analyses of all primary and secondary e...

Full description

Bibliographic Details
Main Authors: Iain B. McInnes, Koji Kato, Marina Magrey, Joseph F. Merola, Mitsumasa Kishimoto, Derek Haaland, Liang Chen, Yuanyuan Duan, Jianzhong Liu, Ralph Lippe, Peter Wung
Format: Article
Language:English
Published: Adis, Springer Healthcare 2022-10-01
Series:Rheumatology and Therapy
Subjects:
2-year
Adalimumab
Janus kinase (JAK) inhibitor
Non-biologic disease-modifying anti-rheumatic drug (non-bDMARD)
Psoriatic arthritis (PsA)
Safety
Online Access:https://doi.org/10.1007/s40744-022-00499-w

Internet

https://doi.org/10.1007/s40744-022-00499-w

Similar Items